This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Stocks in play: Satellos Bioscience Inc.
Today announced the publication in Nature Communications of new research from a scientific team at the Ottawa Hospital Research Institute (OHRI) that validates the company’s novel approach to treating the underlying cause of Duchenne muscular dystrophy and other diseases. Satellos Bioscience Inc. shares T.MSCL are trading down $0.03 at $0.75.
